

Biennial report

Study Groups

Study Group on Cardiovascular involvement in Inflammatory arthritis (CVIIA)

Study Group Leader's name: **Fabiola Atzeni**; Zoltan Szekanecz; Mike Nurmohamed;

Date of annual report submission: 24 April 2020

Summary of last year's activities

- Active involvement in EULAR task force "EULAR Recommendations for cardiovascular risk management in Rheumatic and Musculoskeletal Diseases including SLE and antiphospholipid syndrome"
- The team leader has contacted several investigators to compile a database for prospective CVD follow-up.
- We have submitted several proposals to investigate the cardiovascular effects of new biological agents and "New Chemical Entities"

For 2020 we will continue with our aims defined in 2018. In addition we are considering to develop and Atlas/Library of the most relevant ecocardiographic, TC, MR, etc. images indicative of the cardiovascular involvement in RA and SpA

Main publications

Atzeni F, Nucera V, Galloway J, Zoltán S, Nurmohamed M. Cardiovascular risk in ankylosing spondylitis and the effect of anti-TNF drugs: a narrative review. *Expert Opin Biol Ther.* 2020 May;20(5):517-524. doi: 10.1080/14712598.2020.1704727. Epub 2019 Dec 17.

Atzeni F, Svenungsson E, Nurmohamed MT. Do DMARDs and biologic agents protect from cardiovascular disease in patients with inflammatory arthropathies? *Autoimmun Rev.* 2019 Dec;18(12):102401.

Agca R, Heslinga SC, Rollefstad S, Heslinga S, Södergren A, Semb AG, Kitas GD, Sattar N, Nurmohamed MT; EULAR task force "EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update". Response to: "Influence of changes in cholesterol levels and disease activity on the 10-year cardiovascular risk estimated with different algorithms in rheumatoid arthritis patients" by Fornaro *et al.* *Ann Rheum Dis.* 2019 Aug 14. pii: annrheumdis-2019-215748. doi: 10.1136/annrheumdis-2019-215748.